Maybe tell him even the most basic communication on FB or X would do wonders.

Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea

July 04, 2024 09:30 ET | Source: Rafarma Pharmaceuticals Inc.

Share

Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country.

Currently, procedure is underway to register Yttrium 90 microspheres produced by Rafarma in South Korea, with a view to their subsequent pharmaceutical distribution in Korea. South Korea is the only Asian country with health insurance to use yttrium 90 microspheres for liver cancer patients.

Nanostructured Rafarma microspheres are intended for the treatment of liver cancer, and can also be used for radioembolization of other solid tumors.

Rafarma develops and implements a variety of radionuclide therapy technologies for the treatment of liver cancer and other solid tumors, which can provide a higher quality of life for the patient and delay the development of the disease.

The main idea of ??radionuclide therapy is the delivery of radioactive isotopes directly to the tumor and its subsequent destruction by ionizing radiation. Similar treatment technologies with different methods of delivering radionuclides have been successfully used to treat various diseases.

The principle of action of microspheres: embolization (blockage) of tumor vessels; selective accumulation in the tumor and its destruction by targeted irradiation; microspheres with Yttrium-90 are administered intra-arterially, which ensures that the maximum number of tumor foci is affected, so it is advisable to use them for the treatment of metastases.

Advantages of using microspheres: minimally invasive administration process; minimal damage to healthy tissue; damage to all foci and metastases of the tumor at once; the ability to deliver almost any dose of radiation to the tumor.

Efficiency of use: the average survival of patients when using microspheres with yttrium and chemotherapy increased from 13 to 27 months compared with the use of chemotherapy alone; 89% of patients have a positive response to treatment; 27% experience a decrease in tumor size.

ABOUT RAFARMA PHARMACEUTICALS

Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging, and many other fields at the moment.

For more information, please visit https://www.noyarp.com

CONTACTS:
RAFARMA PHARMACEUTICALS
babenko_press@rafapharm.com
+1 (307) 218-0292
Sheridan, Wyoming, 82801, USA

Source: Rafarma Pharmaceuticals, Inc.
https://www.globenewswire.com/news-release/2024/07/04/2908712/0/en/Rafarma-pharmaceutical-updates-registration-of-Rafarma-microspheres-in-South-Korea.html

Why type of account did you open? An individual cash account is not available to US citizens. I just went through the process and was asked for my address and when USA here is what you get - "Sorry, this type of account is not available for U.S. residents
As a U.S. resident, you can only open a registered self-directed Questrade account if you’re transferring a registered account from another Canadian financial institution."

THIS SUCKS. I can't average down my .02456 avg. Someone please buy for me. I will gladly pay you.

Unfreakin believable!

$ASST inks HUGH deal with LIVE NATION announced in recent filing and NO PR from the company yet. BOOM TIME!!!!

Crypto venture capitalists have restarted investing in crypto, investing $2.5 billion globally in startups this past quarter, per PitchBook.

Thank you!

Do you have Liza Babenko's email or the ability to add me to the WhatsApp group. I missed the call yesterday and was not given notice. She has told me multiple time she would add me but has yet to do so.

NTBL AI presents cancer updates on Monday and Tuesday at AACR

What platform are you bidding on? I am unable to on all of mine at this time.

Late Filing

Unusual activity today

Last one here be sure to turn off the lights!

Website has been taken down. Lights out.

Well they certainly have had enough time to complete all back filings by now. What is the holdup?

HQ Global Education, Inc. Prepares for Return to OTC Markets Current Information Status
Fri, January 12, 2024 at 9:30 AM EST
LOS ANGELES, CA - (NewMediaWire) - January 12, 2024 - HQ Global Education, Inc. (OTC: HQGE) announced today that the company has begun the process of completing its quarterly reports and expects to have them filed and to receive official confirmation of its return to "Current Information" on OTC Markets very soon.

HQGE President Marvin Williams explained, "It is unfortunate that due to some late filings of quarterly reports, HQGE was downgraded to Limited Information" status on OTC Markets. We are now very close to having these reports ready to file, after which they will be reviewed by OTC Markets and the company will once again return to Current Information' status. Meanwhile, I am happy to report that work is continuing unabated at our operating subsidiary Big M Entertainment, and that this issue will not impede us in any way as we continue to move forward with our exciting plans for 2024."

https://finance.yahoo.com/news/hq-global-education-inc-prepares-143000829.html

Where was this posted please?

Where did you see this? Thanks

Interesting. I see no explanation of anything having to do with Cannabis Global or any relationship. I IM'd a few questions. Let's see if they respond giving CBGL responds to nothing at all.

$RAFA - Rafarma Pharmaceuticals Signed a Preliminary Agreement for Radiopharmaceutical Production Center

$RAFA - Rapharma and Kelun Lifesciences have entered into a preliminary agreementhttps://t.co/9Vo7DELkBx pic.twitter.com/QFpR2mLhxR

— Rafarma Pharmaceuticals Inc (@RafarmaPharma) December 6, 2023

$RAFA - Rafarma Pharmaceuticals Signed a Preliminary Agreement for Radiopharmaceutical Production Centerhttps://t.co/AnfNPhwAtM pic.twitter.com/1lIgbQSd8L

— Rafarma Pharmaceuticals Inc (@RafarmaPharma) December 6, 2023

And there was the shakeout. Weak hands gone

They will pump to the .25 range 50 day MA before announcing an offering most likely.

This S*#! is a gut buster!!! MCOM, a pioneer in the urban transportation industry, previously announced that its shareholders approved a reverse stock split of its common stock at a ratio of 150-for-1.

Charles Munger has passed away. Maybe Sal can fill his seat.

Is there any info on the reason for the name change?

Short Interest:

And the Quarterly is out for you viewing pleasure.

This S*%#! is priceless. Keep em coming Sal!!!

Last day for them to release the quarterly is today after Notification of Late Filing.

Unfortunately that move is down.

.0987

Come on this is Sal you're talking about!

Just kickin' a dead horse.

EZGO Insider Buying - The Reporting Person purchased 2,116,897 Ordinary Shares of the Issuer on November 2, 2023, for a total purchase price of $208,938. This purchase was made with his personal funds. The 3,034,200 Ordinary Shares previously purchased by WXYZ Group were all purchased from the working capital of WXYZ Group. https://ih.advfn.com/stock-market/NASDAQ/ezgo-technologies-EZGO/stock-news/92474479/form-sc-13d-general-statement-of-acquisition-of

MCOM fell 4.28% while EZGO was up 15% yesterday and up another 15% premarket today

.136 Pre Market

MCOM - 4.28 while that Chinese stock is +15.15%. It's a good day!
The charts don't lie.

Insignificant. Might be up but you can't sell. Bid still .0017
Looks good on paper but that's about it.